Skip to main content
SpringerLink
Log in

Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the results of gonadotropin-releasing hormone agonist (GnRHa) and gonadotropin-releasing hormone antagonist (GnRHant) use in two demographically matched groups of normoresponder in-vitro fertilisation or intracytoplasmic sperm injection (IVF/ICSI) patients in a prospective study.

Methods

We randomised 93 patients undergoing IVF/ICSI between May 2005 and August 2006. Patients with IVF indications were included except for those with polycystic ovary syndrome or azoospermia, women older than 38 years and those with follicle-stimulating hormone (FSH) ≥10 IU/ml. Patients were stimulated with standard 225 IU recombinant FSH. In Group I (n=45) a daily dose of GnRHant cetrorelix acetate 0.25 mg was administered when follicles reached a diameter of ≥14 mm. Group II (n=48) patients were desensitised with the GnRHa, leuprolide acetate, in a long protocol. Human chorionic gonadotropin (hCG) was administered when at least three follicles of 18 mm in diameter were observed. Oocyte retrieval was scheduled 36 hours following hCG administration and embryos were transferred on day 3 after oocyte retrieval.

Results

The two groups were homogenous for age, infertility duration, basal FSH and serum oestradiol (E2) (P=0.537, P=0.911, P=0.103 and P=0.733, respectively). In Group II (the GnRHa group) more antral follicles (P<0.001), a longer induction duration (P=0.017) and higher peak E2 levels (P<0.001) were observed. No differences were observed in the number of oocytes retrieved (P=0.749), embryos achieved and transferred (P=0.677), or fertilisation rates (P=0.839) between the two groups. There was no statistically significant difference between groups in clinical pregnancy rates, cycle cancellation and ovarian hyperstimulation (P=0.437, P=0.109 and P=0.415, respectively).

Conclusion

GnRHant and GnRHa provide comparable results in normoresponder patients, while GnRHant allows a greater flexibility in their treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of the embryos after in vitro fertilization. N Engl J Med. 1998;339:573–577.

    Article  PubMed  CAS  Google Scholar 

  2. Albano C, Smitz J, Camus M, et al. Hormonal profile during the follicular phase in cycles stimulated with recombination of human menopausal gonadotropin and gonadotropin-releasing hormone antagonist (Cetrorelix). Hum Reprod. 1996;11:14–18.

    Google Scholar 

  3. Rivier JE, Porter J, Rivier CL. New effective GnRH antagonists with minimal potency for histamine release in vitro. J Med Chem. 1986;29:1846–1851.

    Article  PubMed  CAS  Google Scholar 

  4. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;(3):CD001750.

  5. Hohmann FP, Macklon NS, Fauser BCJM. A randomized comparison of two ovarian stimulation protocols with GnRH antagonist cotreatment for IVF commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRHa protocol. J Clin Endocrinol Metab. 2003;88:166–173.

    Article  PubMed  CAS  Google Scholar 

  6. Kolibianakis EM, Albano C, Kahn J, Camus M. Exposure to high levels of luteinizing hormone and estradiol in early follicular phase of GnRH antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003;79:603–607.

    Article  Google Scholar 

  7. Ludwig M, Katalinic A, Banz C. Tailoring the GnRH antagonist cetrorelix acetate to individual patient’s needs in ovarian stimulation for IVF: results of prospective, randomized study. Hum Reprod. 2002;17:2842–2845.

    Article  PubMed  CAS  Google Scholar 

  8. Mansour RT, Aboulghar MA, Serour GI. The use of clomiphene citrate/human menopausal gonodotropins in conjunction with GnRH antagonist in an IVF/ICSI program is not a cost effective protocol. Acta Obstet Gynecol Scand. 2003;82:48–52.

    Article  PubMed  Google Scholar 

  9. Hwang J-L, Huang L-W, Hsieh B-C. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod. 2003;18:45–49.

    Article  PubMed  CAS  Google Scholar 

  10. Del Gadillo JCB, Siebzehnrübl E, Dittrich R. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. Eur J Obstet Gynecol Reprod Biol. 2002;102:179–183.

    Article  PubMed  Google Scholar 

  11. Ragni G, Vegetti W, Baroni E. Comparison of luteal phase profile in gonadotropin stimulated cycles with or without a gonadotropin-releasing hormone antagonist. Hum Reprod. 2001;16:2258–2262.

    Article  PubMed  CAS  Google Scholar 

  12. Practice Committee of the Society for Assisted Reproductive Technology; Practice Committee of the American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril. 2006;86(5 suppl):51–52.

    Google Scholar 

  13. Londra L, Inza R, Lombardi E, Marconi G, Young E, Kenny A. GnRh antagonist versus GnRh agonist in good prognosis IVF patients. Hum Reprod. 2003;18(suppl 1):114.

    Google Scholar 

  14. Borm G, Mannaerts B, for the European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod. 2000;15:1490–1498.

    Article  PubMed  CAS  Google Scholar 

  15. Olivennes F, Belaisch-Allart J, Emperaire JC. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314–320.

    Article  PubMed  CAS  Google Scholar 

  16. Fluker M, Grifo J, Leader A, Levy M, for the North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38–45.

    Article  PubMed  CAS  Google Scholar 

  17. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644–651.

    Article  Google Scholar 

  18. Bahceci M, Ulug U, Ben-Shlomo I. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med. 2005;50:84–90.

    PubMed  CAS  Google Scholar 

  19. Zikopoulos K, Kapanis A, Adonakis G. A prospective randomized study comparing gonadotropin releasing hormone agonists or gonadotropin releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia Fertil Steril. 2005;83:1354–1362.

    Article  PubMed  CAS  Google Scholar 

  20. Check ML, Check JH, Choel JK. Effect of antagonists versus agonists on in vitro fertilization outcome. Clin Exp Obstet Gynecol. 2004;31:257–259.

    Article  PubMed  CAS  Google Scholar 

  21. Causio F, Sarcina E, Leonetti T. GnRH agonist versus GnRH antagonist in an IVF programme: luteal phase hormonal characteristics. Hum Reprod. 2004;19:i103.

    Google Scholar 

  22. Albano C, Felberbaum RE, Smitz J. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormonereleasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod. 2000;15:526–531.

    Article  PubMed  CAS  Google Scholar 

  23. Badrawy A, Al-Inany H, Hussein M, Zaki S, Ramzy AM. Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertil Soc J. 2005;10:49–54.

    Google Scholar 

  24. Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil Steril. 2005;83:1700–1707.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zekai Tahir Burak Women’s Health and Education Hospital, Ankara, Turkey

    Ozlem Moraloglu, Sevtap Kilic, Rana Karayalçin, Beril Yuksel, Nicel Tasdemir, Ayça Işik & Mustafa Ugur

Authors
  1. Ozlem Moraloglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sevtap Kilic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rana Karayalçin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Beril Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicel Tasdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ayça Işik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa Ugur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sevtap Kilic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moraloglu, O., Kilic, S., Karayalçin, R. et al. Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients. Adv Therapy 25, 266–273 (2008). https://doi.org/10.1007/s12325-008-0028-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0028-8

Keywords

Search

Navigation